Search Tag: bevacizumab

Cardiology Management

Study: Bevacizumab increases risk of arterial adverse events

2017 12 Sep

The monoclonal antibody bevacizumab effectively inhibits angiogenesis in several types of cancers by blocking vascular endothelial growth factor. However, a new analysis reveals that treatment with bevacizumab increases the risk of arterial adverse events, particularly cardiac and cerebral ischaemia, venous adverse events, bleeding, and arterial hypertension.... Read more